Scholar Rock Holding Corp

Scholar Rock Reports Third Quarter 2026 Financial Results and Recent Business Highlights

U.S. launch of ISEMBYLD™ (apitegromab-mstn), the first and only muscle-targeted therapy for children and adults living with spinal muscular atrophy…